Expression profile of the WNT3A genein ductal breast carcinoma
DOI:
https://doi.org/10.12923/cipms-2026-0008Keywords:
WNT3A, breast cancer, fibroadenoma, qRT-PCR, Wnt/β-catenin pathway, biomarkerAbstract
Breast cancer is one of the leading causes of cancer-related mortality among women worldwide. The Wnt/β-catenin signaling pathway, particularly the WNT3A ligand, plays a pivotal role in mammary gland homeostasis and tumorigenesis. However, its expression profile in malignant and benign breast lesions remains unclear. This study aimed to evaluate the expression level of the WNT3A gene in ductal breast carcinoma compared with benign fibroadenoma tissues and to assess its potential diagnostic and prognostic value. Breast tissue samples were obtained from 31 women with ductal carcinoma and 14 women with fibroadenoma. WNT3A expression was analyzed using quantitative real-time polymerase chain reaction, with β-actin as the endogenous control. Statistical analyses included the ΔCt method, the Mann-Whitney U test, Pearson correlation, logistic regression, and receiver operating characteristic (ROC) analysis. WNT3A expression was significantly lower in ductal carcinoma tissues than in fibro-adenoma samples (fold change = 0.32; p = 0.043). ROC analysis demonstrated moderate discriminatory power (AUC = 0.695; specificity = 0.87; sensitivity = 0.46). No significant correlations were observed between WNT3A expression and age, tumor size, lymph node involvement, or prognostic stage. Logistic regression revealed a non-significant trend toward increased cancer risk associated with decreased WNT3A expression (OR = 1.442; p = 0.153). Downregulation of WNT3A may differentiate malignant from benign breast lesions and may reflect early dysregulation of the Wnt signaling pathway. Although not associated with clinical stage or TNM classification, WNT3A shows potential as a diagnostic biomarker and warrants further investigation.
References
1. Patel DK, Kesharwani R, Verma A, AlAbbasi FA, Anwar F, Kumar V. Scope of Wnt signaling in the precise diagnosis and treatment of breast cancer. Drug Discov Today. 2023;28:103597. https://doi.org/10.1016/j.drudis.2023.103597
2. Abreu de Oliveira WA, El Laithy Y, Bruna A, Annibali D, Lluis F. Wnt signaling in the breast: from development to disease. Front Cell Dev Biol. 2022;10:884467. https://doi.org/10.3389/fcell.2022.884467
3. Xue C, Chu Q, Shi Q, Zeng Y, Lu J, Li L. Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances. Signal Transduct Target Ther. 2025;10:106.
4. Song P, Gao Z, Bao Y, Chen L, Huang Y, Liu Y, et al. Wnt/βcatenin signaling pathway in carcinogenesis and cancer therapy. J Hematol Oncol. 2024;17:46.
5. He S, Lu Y, Liu X, Huang X, Keller ET, Qian CN, et al. WNT3A: functions and implications in cancer. Chin J Cancer. 2015;34:50.
6. Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt/βcatenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7:3. https://doi.org/10.1038/s41392021007626
7. Qi L, Sun B, Liu Z, Cheng R, Li Y, Zhao X. WNT3A expression is associated with epithelialmesenchymal transition and promotes colon cancer progression. J Exp Clin Cancer Res. 2014;33:107.
8. Cserni G, Chmielik E, Cserni B, Tot T. The new TNM-based staging of breast cancer. Virchows Arch. 2018;472:697-703.
9. Sawaki M, Shien T, Iwata H. TNM classification of malignant tumors: breast cancer study group. Jpn J Clin Oncol. 2019;49:228-231.
10. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25:402-408.
11. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3:1101-8.
12. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an opensource package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.
13. Xu X, Zhang M, Xu F, Jiang S. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. Mol Cancer. 2020;19:165.
14. Benhaj K, Akcali KC, Ozturk M. Redundant expression of canonical Wnt ligands in human breast cancer cell lines. Oncol Rep. 2006;15(3): 701-7. https://doi.org/10.3892/or.15.3.701
15. Katoh M. Regulation of WNT3 and WNT3A mRNAs in human cancer cell lines NT2, MCF7, and MKN45. Int J Oncol. 2002;20: 373-7.
16. Kaiser A, Eiselt G, Bechler J, Huber O, Schmidt M. WNT3A signaling inhibits aromatase expression in breast adipose fibroblasts: a possible mechanism supporting the loss of estrogen responsiveness of triplenegative breast cancers. Int J Mol Sci. 2023;24:4654. https://doi.org/10.3390/ijms24054654
17. Huguet EL, McMahon JA, McMahon AP, Bicknell R, Harris AL. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res. 1994;54:2615-21.
18. Biechele TL, Camp ND, Fass DM, Kulikauskas RM, Robin NC, White BD, et al. Chemicalgenetic screen identifies riluzole as an enhancer of Wnt/βcatenin signaling in melanoma. Chem Biol. 2010;17:1177-82.
19. Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, et al. Myelomaderived Dickkopf1 disrupts Wntregulated osteoprotegerin and RANKL production by osteoblasts. Blood. 2008;112:196-207.
20. Lamb R, Ablett MP, Spence K, Landberg G, Sims AH, Clarke RB. Wnt pathway activity in breast cancer subtypes and stemlike cells. PLoS One. 2013;8:e67811.
21. Andrade Filho PA, Letra A, Cramer A, Prasad JL, Garlet GP, Vieira AR, et al. Insights from studies with oral cleft genes suggest associations between WNTpathway genes and risk of oral cancer. J Dent Res. 2011;90:740-6.
22. Takei Y, Takigahira M, Mihara K, Tarumi Y, Yanagihara K. The metastasisassociated microRNA miR516a3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer. Cancer Res. 2011;71:1442-53.
23. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, et al. The miR15a/miR161 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008;14:1271-77.
24. Kaur N, Chettiar S, Rathod S, Rath P, Muzumdar D, Shaikh ML, et al. WNT3Amediated activation of Wnt/βcatenin signaling promotes tumor progression in glioblastoma. Mol Cell Neurosci. 2013;54:44-57.
25. Tufail M, Jiang CH, Li N. Wnt signaling in cancer: from biomarkers to targeted therapies and clinical translation. Mol Cancer. 2025; 24:107.
26. Lüönd F, Tiede S, Christofori G. Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. Br J Cancer. 2021;125:164-75.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Joanna Łuszczak, Marta Ziaja-Sołtys, Daniel Zalewski (Autor)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
